Literature DB >> 17440275

Inflammation in dry age-related macular degeneration.

Eduardo B Rodrigues1.   

Abstract

PURPOSE: To summarize the current information regarding the role of immune and inflammatory response in the pathogenesis of dry age-related macular degeneration (ARMD).
METHODS: A Pubmed search was conducted of the period January 1999 to 2005. Relevant information in the literature on the role of inflammation in early dry ARMD was reviewed.
RESULTS: Some important evidence for inflammation in early ARMD consists in the isolation of immunoglobulins, complement proteins, cytokines and activated microglia, in retinal pigment epithelium (RPE) cells and drusen. Pivotal mechanisms in early ARMD include the accumulation of debris and proteins along the RPE surface, followed by immune-complex deposition and complement activation. In contrast, the role of other plasma enzymes such as kallikrein-kinin-bradykinin, the Hageman factor, peptides and coagulation proteins in drusen formation and ARMD has yet to be determined.
CONCLUSION: A clear role for inflammatory mediators and cells has been established in recent years. Future studies should elucidate further mechanisms in ARMD development. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440275     DOI: 10.1159/000099293

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  24 in total

1.  Treatment of dry age-related macular degeneration with dobesilate.

Authors:  P Cuevas; L A Outeiriño; J Angulo; G Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-06-21

2.  Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography.

Authors:  Joseph Ho; Andre J Witkin; Jonathan Liu; Yueli Chen; James G Fujimoto; Joel S Schuman; Jay S Duker
Journal:  Ophthalmology       Date:  2010-11-20       Impact factor: 12.079

3.  IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells.

Authors:  Xiao-Cui Liu; Xiao-Fei Liu; Cong-Xiang Jian; Chen-Jun Li; Shou-Zhi He
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

4.  Identification of human plasma proteins as major clients for the extracellular chaperone clusterin.

Authors:  Amy R Wyatt; Mark R Wilson
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

5.  Elevated neutrophil-to-lymphocyte ratio in pseudoexfoliation syndrome.

Authors:  B E Kurtul; P A Ozer; E U Kabatas
Journal:  Eye (Lond)       Date:  2016-05-06       Impact factor: 3.775

6.  Acute phase proteins are major clients for the chaperone action of α₂-macroglobulin in human plasma.

Authors:  Amy R Wyatt; Nathan W Zammit; Mark R Wilson
Journal:  Cell Stress Chaperones       Date:  2012-08-16       Impact factor: 3.667

7.  Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF.

Authors:  Stephen J Kim; Hassanain S Toma; Joshua M Barnett; John S Penn
Journal:  Exp Eye Res       Date:  2010-07-24       Impact factor: 3.467

8.  Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.

Authors:  Philip A Petrou; Denise Cunningham; Katherine Shimel; Molly Harrington; Keri Hammel; Catherine A Cukras; Frederick L Ferris; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-18       Impact factor: 4.799

9.  Downregulation of p22phox in retinal pigment epithelial cells inhibits choroidal neovascularization in mice.

Authors:  Qiuhong Li; Astra Dinculescu; Zhiying Shan; Rehae Miller; Jijing Pang; Alfred S Lewin; Mohan K Raizada; William W Hauswirth
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

10.  Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD.

Authors:  Wenxin Ma; Lian Zhao; Aurora M Fontainhas; Robert N Fariss; Wai T Wong
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.